Events
TCR-based Therapies for Solid Tumors Summit
Come see us at TCR-based Therapies for Solid Tumors Summit
6/27 – 6/29 in Boston
Katja Fink, PhD, Msc MOT
Senior Director of Discovery
Katja be presenting on “Discovery of TCRs targeting novel antigens using Deep Immunomics”.
FOCIS 2022
Come see us at FOCIS
6/21 – 6/26 in San Francisco, CA
Katja Fink, PhD, Msc MOT
Senior Director of Discovery
Tuesday June 21, 2022 from 6:15 PM – 7:45 PM
Poster Number: Tu80
Katja will be presenting a poster on “Discovery of T cell receptors for Adoptive T cell Therapy against Solid Tumors”.
BIO 2022
Come see us at BIO 2022
6/13 – 6/16 in San Diego, CA
Come meet ImmunoScape at BIO 2022 to learn about the discovery and development of novel T Cell Receptor-based therapeutics in solid tumor oncology using our Deep Immunomics platform.
Visit us at RECOMB 2022
Come see us at RECOMB 2022
5/22-5/25 in La Jolla, CA
Poster #29
Florian Schmidt, PhD will be presenting on “Machine learning to predict viral specificity of CD8+ T cells from high throughput multi-omics data”.
Click here to view our Poster at RECOMB 2022
The Mass Cytometry Summit 2021 – Igniting Insight into Human Health
Michael Fehlings, PhD., ImmunoScape’s VP of Operations and Development, will be presenting on,”SARS-CoV-2 specific CD8+ T cell responses in convalescent COVID-19 individuals” on May 25 at 11:00-11:30 am PT.
The CyTOF® Edge will be a half day virtual event taking place on 25th May 2021.
The focus will be on clinical and translational investigators using CyTOF technology to gain cell biology insights and develop new ways to diagnose and treat human disease in the areas of immunooncology and infectious disease research.
The Bio Report Podcast: Characterizing the Immunome at Scale
ImmunoScape’s Senior Director of Business Development/Lead of the Vaccine Task Force, Dr. Brian Abel did a Bio Report podcast with Daniel Levine on Characterizing the Immunome at Scale discussing a collaborative study with National Institutes of Health’s National Institute of Allergy and Infectious Diseases and Johns Hopkins University about the ability of people infected with COVID-19 to produce an immune response to new variants of the virus, the company’s technology, and how it is being used to develop the next generation of immunotherapies.
Click here to hear the podcast
BIOCOM 2021
Geoff Nosrati, Ph.D., ImmunoScape’s Chief Business Officer, will be presenting on, “Advancing the development of next-generation therapeutics with the Deep Immunomics platform.” at Biocom’s upcoming Global Life Science Partnering Conference.
Session date: February 25th, 2021
Session time: 10:00-10:14am PST
World Vaccine & Immunotherapy 2020
Please join our oral presentation on, “Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation” and meet our team.
Session Date: Tuesday, December 1, 2020
Session Time: 4:20 PM PST
Come visit ImmunoScape’s virtual booth at the WVIC 2020, December 1-3, 2020 and chat with us.
In this study, using our multiplexed peptide-MHC tetramer approach to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition, we identified 52 unique epitope hits (18 unreported), spanning different viral proteins. Insights gained from these SARS-CoV-2 reactivities and their associated T cell profiles capable of differentiating into long-term mediators of protection may guide the rational design of COVID-19 vaccine candidates to curb this pandemic.
IDWeek 2020™
October 21-25, 2020
Please join our oral presentation on, “Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation” and meet our team!
Session Date: Saturday October 24, 2020
Session Time: 1:15 PM – 3:00 PM
Come visit ImmunoScape’s virtual booth at the IDWeek 2020™ and chat with us!
In this study, using our multiplexed peptide-MHC tetramer approach to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition, we identified 52 unique epitope hits (18 unreported), spanning different viral proteins. Insights gained from these SARS-CoV-2 reactivities and their associated T cell profiles capable of differentiating into long-term mediators of protection may guide the rational design of COVID-19 vaccine candidates to curb this pandemic.
The Digital International Liver Conference™ 2020
August 27-29, 2020
Virtual event
ImmunoScape and Gilead Sciences recently presented findings at the Digital International Liver Congress 2020 that demonstrated the feasibility of simultaneously identifying and deeply characterizing rare HBV-specific T cells in heterogeneous HBV patient cohorts to facilitate the development of more effective therapeutic strategies for hepatitis B virus (HBV) infection.